Comparing SG&A Expenses: Insmed Incorporated vs Axsome Therapeutics, Inc. Trends and Insights

Biotech Giants' SG&A Expenses: A Decade of Growth

__timestampAxsome Therapeutics, Inc.Insmed Incorporated
Wednesday, January 1, 2014139283031073000
Thursday, January 1, 2015241928943216000
Friday, January 1, 2016634364850679000
Sunday, January 1, 2017720669179171000
Monday, January 1, 20189351522168218000
Tuesday, January 1, 201913598030210796000
Wednesday, January 1, 202028896749203613000
Friday, January 1, 202166646205234273000
Saturday, January 1, 2022159253661265784000
Sunday, January 1, 2023323123000344501000
Monday, January 1, 2024411359000
Loading chart...

Infusing magic into the data realm

SG&A Expenses: A Tale of Two Biotechs

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Insmed Incorporated and Axsome Therapeutics, Inc. over the past decade.

A Decade of Growth

From 2014 to 2023, both companies have shown significant growth in their SG&A expenses, reflecting their expanding operations and market presence. Insmed Incorporated's expenses surged by over 1,000%, peaking in 2023, while Axsome Therapeutics, Inc. experienced an exponential increase of more than 23,000% during the same period.

Strategic Investments

This upward trend in SG&A expenses indicates strategic investments in marketing, administration, and sales, essential for driving innovation and capturing market share. As these companies continue to grow, monitoring their financial strategies will provide valuable insights into their future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025